Cortexyme announces lead 3clpro inhibitor for the treatment of coronavirus infection

South san francisco, calif.--(business wire)---- $crtx--cortexyme, inc. (nasdaq: crtx), a company advancing a pivotal trial in alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3clpro inhibitor (cor803) for treatment of coronavirus infections, including covid-19 disease, caused by sars-cov-2 infection. “there continues to be a large unmet need for coronavirus treatment. the targ
QNCX Ratings Summary
QNCX Quant Ranking